Skip to main content
Erschienen in: Intensive Care Medicine 5/2007

01.05.2007 | Correspondence

Linezolid as rescue therapy for pneumococcal meningitis

verfasst von: Paula Ramírez, Jose M. Sahuquillo, Concepción Cortés, Pedro Kot, Juan M. Bonastre

Erschienen in: Intensive Care Medicine | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Excerpt

The classic treatment of choice for acute meningitis due to penicillin-resistant Streptococcus pneumoniae is the combination of a third-generation cephalosporin, vancomycin, and dexamethasone [1]. However, the frequent existence of multiresistant strains and the appearance on the market of new antibiotics with better bioavailability could make it necessary for us to reconsider the choice. …
Literatur
1.
Zurück zum Zitat Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:1267–1284CrossRefPubMed Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ (2004) Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39:1267–1284CrossRefPubMed
2.
Zurück zum Zitat Mason EO, Lamberth LB, Kaplan SL (1996) In vitro activities of oxazolidones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1039–1040PubMedPubMedCentral Mason EO, Lamberth LB, Kaplan SL (1996) In vitro activities of oxazolidones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 40:1039–1040PubMedPubMedCentral
3.
Zurück zum Zitat Spangler SK, Jacobs MR, Appelbaum PC (1996) Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 40:481–484PubMedPubMedCentral Spangler SK, Jacobs MR, Appelbaum PC (1996) Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 40:481–484PubMedPubMedCentral
4.
Zurück zum Zitat Moellering RC (2003) Linezolid: the first oxazolidone antimicrobial. Ann Intern Med 138:135–142CrossRefPubMed Moellering RC (2003) Linezolid: the first oxazolidone antimicrobial. Ann Intern Med 138:135–142CrossRefPubMed
6.
Zurück zum Zitat Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Tauber MG (2000) Linezolid against penicillin-sensitive and penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46:981–985CrossRefPubMed Cottagnoud P, Gerber CM, Acosta F, Cottagnoud M, Neftel K, Tauber MG (2000) Linezolid against penicillin-sensitive and penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 46:981–985CrossRefPubMed
7.
Zurück zum Zitat Faella F, Pagliano P, Fusco U, Attanasio V, Conte M (2006) Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect 12:391–394CrossRefPubMed Faella F, Pagliano P, Fusco U, Attanasio V, Conte M (2006) Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect 12:391–394CrossRefPubMed
Metadaten
Titel
Linezolid as rescue therapy for pneumococcal meningitis
verfasst von
Paula Ramírez
Jose M. Sahuquillo
Concepción Cortés
Pedro Kot
Juan M. Bonastre
Publikationsdatum
01.05.2007
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 5/2007
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-007-0557-7

Weitere Artikel der Ausgabe 5/2007

Intensive Care Medicine 5/2007 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.